Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness

Executive Summary

Inability to chew Arymo ER tablet helps Egalet overcome questions about clinical meaningfulness of human oral abuse study results; advisors also back intranasal, intravenous deterrence claims.

Advertisement

Related Content

Off-Label Opioid Promotion: US FDA ‘Does Not Object’ To Intranasal Deterrence Data, Egalet Says
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
Recent And Upcoming FDA Advisory Committee Meetings
If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market
Recent And Upcoming FDA Advisory Committee Meetings
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Opioids With Abuse-Deterrent Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel